Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25A | P30304 | 1/20 | 0.36 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1962073 | 0.98 | CDC25A (0.37) | CDC25ACTDSP1LMNATSHRTHRB | |
| Iodide SCHEMBL10751393 | 0.95 | CTDSP1 (0.39) | CDC25ACTDSP1LMNATSHRTHRB | |
| SCHEMBL9936179 | 0.95 | CDC25A (0.36) | CDC25ACTDSP1LMNATSHRTHRB | |
| Water SCHEMBL11593967 | 0.95 | CDC25A (0.36) | CDC25ACTDSP1LMNATSHRTHRB | |
| SCHEMBL9935048 | 0.95 | CDC25A (0.36) | CDC25ACTDSP1LMNATSHRTHRB | |
| SCHEMBL12638482 | 0.93 | CDC25A (0.38) | CDC25ACTDSP1LMNATSHRTHRB | |
| SCHEMBL3308384 | 0.93 | CTDSP1 (0.41) | CDC25ACTDSP1LMNATSHRTHRB | |
| Bromide SCHEMBL829698 | 0.91 | CTDSP1 (0.41) | CDC25ACTDSP1LMNATSHRTHRB | |
| Hydrochloric Acid SCHEMBL11781908 | 0.91 | CDC25A (0.41) | CDC25ACTDSP1TSHRTHRB | |
| SCHEMBL8965122 | 0.91 | CDC25A (0.41) | CDC25ACTDSP1TSHRTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6806371-B2 | BY MEANS OF PHASE TRANSFER CATALYSIS | DSM FINE CHEMICALS AUSTRIA NFG GMBH & CO KG (AT) | 2004-10-19 | — | — | US | disclosed |
| EP-1405847-A1 | Process to prepare substituted pyridine-N-oxide compounds | DSM Fine Chemicals Austria Nfg GmbH & Co KG (AT) | 2004-04-07 | — | — | EP | disclosed |
| US-20040063957-A1 | Preparation of substituted pyridine N-oxide compounds | DSM FINE CHEMICALS AUSTRIA NFG GMBH & COKG (AT) | 2004-04-01 | — | — | US | disclosed |
| EP-0269884-B1 | CATALYZED ALKYLATION OF HALOPYRIDINATES IN THE ABSENCE OF ADDED ORGANIC SOLVENTS | DOWELANCO (US) | 1991-09-25 | — | — | EP | disclosed |
| EP-0277292-B1 | ORGANIC SOLVENT-FREE PROCESS FOR PREPARING PYRIMIDINYL ORGANOPHOSPHATES | THE DOW CHEMICAL COMPANY (US) | 1991-05-08 | — | — | EP | disclosed |
| EP-0277292-A1 | Organic solvent-free process for preparing pyrimidinyl organophosphates | THE DOW CHEMICAL COMPANY (US) | 1988-08-10 | — | — | EP | disclosed |
| EP-0269884-A1 | Catalyzed alkylation of halopyridinates in the absence of added organic solvents | DOWELANCO (US) | 1988-06-08 | — | — | EP | disclosed |
| US-4701531-A | Catalyzed alkylation of halopyridinates in the absence of added organic solvents | THE DOW CHEMICAL COMPANY (US) | 1987-10-20 | — | — | US | disclosed |
| US-4699634-A | SEMIPERMEABLE MEMBRANES | THE STANDARD OIL COMPANY (US) | 1987-10-13 | — | — | US | disclosed |
| US-4546189-A | Preparation of cyano(6-(substituted phenoxy)-2-pyridinyl)methyl esters of 3-(2,2-dihaloethenyl)-2,2-dimethylcyclopropane carboxylic acids | THE DOW CHEMICAL COMPANY (US) | 1985-10-08 | — | — | US | disclosed |
| US-4092312-A | CATALYST SYSTEM OF A QUATERNARY AMMONIUM SALT AND 1,4-DIAZABICYCLO(2.2.2)OCTANE | THE DOW CHEMICAL COMPANY (US) | 1978-05-30 | — | — | US | disclosed |
| US-4086253-A | 3,3',5,5'-Tetra-substituted diphenoquinone from 2,6-disubstituted phenol by phase-transfer catalysis | THE DOW CHEMICAL COMPANY (US) | 1978-04-25 | — | — | US | disclosed |
| US-4061682-A | QUATERNARY AMMONIUM OR PHOSPHONIUM SALT | THE DOW CHEMICAL COMPANY (US) | 1977-12-06 | — | — | US | disclosed |
| US-4028439-A | QUATERNARY AMMONIUM SALT AND IMIDAZOLE CATALYSTS | THE DOW CHEMICAL COMPANY (US) | 1977-06-07 | — | — | US | disclosed |
| US-4016225-A | WITH QUATERNARY AMMONIUM SALT AND 1,4-DIAZABICYCLO(2.2.2)OCTANE CATALYST | THE DOW CHEMICAL COMPANY (US) | 1977-04-05 | — | — | US | disclosed |
| US-4007197-A | QUATERNARY AMMONIUM OR PHOSPHONIUM SALT AND TERTIARY AMINE CATALYST | THE DOW CHEMICAL COMPANY (US) | 1977-02-08 | — | — | US | disclosed |
| US-4001293-A | Process for production of γ-halonitriles | THE DOW CHEMICAL COMPANY (US) | 1977-01-04 | — | — | US | disclosed |
| US-3996259-A | QUATERNARY AMMONIUM OR PHOSPHONIUM SALT | THE DOW CHEMICAL COMPANY (US) | 1976-12-07 | — | — | US | disclosed |
| US-3974199-A | Process for production of cyclopropylcyanide | THE DOW CHEMICAL COMPANY (US) | 1976-08-10 | — | — | US | disclosed |
| US-3972887-A | QUATERNARY AMMONIUM SALT CATALYST | THE DOW CHEMICAL COMPANY (US) | 1976-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063957-A1 | Preparation of substituted pyridine N-oxide compounds | HRH2, SCO2, CBR1 | CDC25A 762/4885CTDSP1 2163/4885LMNA 2031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.